New CAR T Cell for Multiple Myeloma Approved by FDA : compar

Ciltacabtagene autoleucel (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.

Related Keywords

United States , American , Sundar Jagannath , American Society Of Hematology , Drug Administration , American Society , Medscape Medical , Mount Sinai , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Hematology , Biologic Therapy , Chimeric Antigen Receptort Cell Therapy , Chimeric Antigen Receptors , Himeric Immunoreceptors , Himerict Cell Receptors , Rtificialt Cell Receptors , Ar T , Dyspnea , Fatigue , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Precision Medicine , Hypogammaglobulinemia ,